Photo from Shawn Day on Unsplash UK-based biotech LoQus23 Therapeutics is advancing an oral small molecule targeting a fundamental genetic process in Huntington’s disease, a rare neurodegenerative disorder.
The Dutch biotech argenx has announced a planned leadership transition to be effective in May after its annual shareholder meeting. Tim Van Hauwermeiren, co-founder and long-time Chief Executive Officer, will transition from CEO to Non-Executive Director and Chairman of the Board of Directors; and Karen Massey, currently Chief Operating Officer, will assume the role of CEO and Executive Director, pending shareholder approval.
On January 4, the French pharma group Servier and the AI drug discovery Insilico Medicine announced a collaboration worth up to $888 million. Insilico will receive up to $32 million from Servier for a multi-year research and development collaboration to discover and develop oncology therapies using Insilico’s artificial intelligence (AI)-driven drug discovery platform and Servier’s cancer development expertise.